NASDAQ:RIGL

Rigel Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy RIGL

*Your capital is at risk

$30.30

+0.280 (+0.93%)

At Close: Jun 03, 2026

Rigel Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 38.61. In total, the insiders bought 738.16K and sold 134.38K RIGL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	38.61
● Buy	738.16K shares
● Sell	134.38K shares
82% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Feb 20, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 38.61. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 01, 2026 Sell	Common Stock F-InKind	Rodriguez Raul R CEO, President	CEO / President	2 424 Value: $72.4K
Jun 01, 2026 Sell	Common Stock F-InKind	Rojkjaer Lisa EVP, Chief Medical Officer	Officer	850 Value: $25.4K
Jun 01, 2026 Buy	Common Stock M-Exempt	Schorno Dean L EVP & Chief Financial Officer	C-Suite Officer	2 181 Value: $27.7K
Jun 01, 2026 Sell	Common Stock F-InKind	Schorno Dean L EVP & Chief Financial Officer	C-Suite Officer	928 Value: $27.7K
Jun 01, 2026 Buy	Common Stock M-Exempt	Schorno Dean L EVP & Chief Financial Officer	C-Suite Officer	1 200 Value: $22.4K
Jun 01, 2026 Buy	Employee Stock Option (right to buy) M-Exempt	Schorno Dean L EVP & Chief Financial Officer	C-Suite Officer	2 181 Value: $27.7K
Jun 01, 2026 Buy	Employee Stock Option (right to buy) M-Exempt	Schorno Dean L EVP & Chief Financial Officer	C-Suite Officer	1 200 Value: $22.4K
Jun 01, 2026 Sell	Common Stock F-InKind	Santos David A EVP, Chief Commercial Officer	Officer	874 Value: $26.1K
Jun 01, 2026 Sell	Common Stock F-InKind	Furey Raymond J. EVP, GC, Cco & Corp Sec	Officer	877 Value: $26.2K
May 26, 2026 Sell	Common Stock S-Sale	Ali-jackson Kamil Director	Director	2 500 Value: $72.9K
May 15, 2026 Buy	Common Stock A-Award	Frohlich Mark W Director	Director	5 750 Value: $166.8K
May 15, 2026 Buy	Common Stock A-Award	Hannah Alison L. Director	Director	5 750 Value: $166.8K
May 15, 2026 Buy	Common Stock A-Award	Miller Michael Patrick Director	Director	5 750 Value: $166.8K
May 15, 2026 Buy	Common Stock A-Award	Moos Walter H Director	Director	5 750 Value: $166.8K
May 15, 2026 Buy	Common Stock A-Award	Wasman Jane Director	Director	5 750 Value: $166.8K
May 15, 2026 Buy	Common Stock A-Award	Lapointe Anthony Gregg Director	Director	5 750 Value: $166.8K
May 15, 2026 Buy	Common Stock A-Award	Ali-jackson Kamil Director	Director	5 750 Value: $166.8K
Feb 20, 2026 Buy	Stock Option (right to buy) M-Exempt	Moos Walter H Director	Director	4 000 Value: $96.0K
Feb 20, 2026 Sell	Common Stock S-Sale	Moos Walter H Director	Director	4 000 Value: $145.4K
Feb 20, 2026 Buy	Common Stock M-Exempt	Moos Walter H Director	Director	4 000 Value: $96.0K
Feb 17, 2026 Buy	Common Stock A-Award	Furey Raymond J. EVP, GC, Cco & Corp Sec	Officer	19 497 Value: $693.1K
Feb 17, 2026 Buy	Common Stock A-Award	Rodriguez Raul R CEO, President	CEO / President	53 915 Value: $1.92M
Feb 17, 2026 Buy	Common Stock A-Award	Rojkjaer Lisa EVP, Chief Medical Officer	Officer	18 894 Value: $671.7K
Feb 17, 2026 Buy	Common Stock A-Award	Schorno Dean L EVP & Chief Financial Officer	C-Suite Officer	20 636 Value: $733.6K
Feb 17, 2026 Buy	Common Stock A-Award	Santos David A EVP, Chief Commercial Officer	Officer	19 430 Value: $690.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT RIGEL PHARMACEUTICALS

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical t...

Read Full Profile Here